Marı́a José Lallena

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Xueqian Gong, Lacey M. Litchfield, Yue Webster et al. · Cancer Cell · 2017 · 236 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene

Xueqian Gong, Jian Du, Stephen H. Parsons et al. · Cancer Discovery · 2018 · 233 citations

Life Sciences, Oncology, Pharmacology +17

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso et al. · Oncotarget · 2017 · 198 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 173 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12